Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kadunilimab plus neoadjuvant chemotherapy for locally advanced cervical cancer
ChiCTR2300074462Phase 2Recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Feb 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, liposomal paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by The First Hospital of Lanzhou University. Primary endpoint: Complete response. Started Feb 2024; status: recruiting.
02
Drugs
cadonilimabliposomal paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2300074462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074462.